Special Issue "Antibody-Mediated Thrombotic Diseases"

Dear colleagues,

In recent years, our knowledge of the interplay between adaptive immunity and hemostasis has increased considerably. One aspect of this connection is the antibody-mediated activation of the coagulation system. Antibody-mediated thrombotic diseases include thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and antiphospholipid syndrome (APS). Antibody-mediated platelet activation also plays a role in COVID-19-induced coagulatopathy, in which thrombotic complications are an important prognostic factor. Recently, vaccine-induced immune thrombotic thrombocytopenia (VITT), a prothrombotic side effect of adenoviral vector-based COVID-19 vaccines, was added to this list of conditions with antibody-mediated thrombosis. Remarkable progress has been made recently in the diagnosis and treatment of thrombotic diseases. Platelet count and thrombosis are important clinical signs. It is critical to identify the cause responsible for thrombocytopenia, but this often proves difficult due to the complex comorbidities. Anticoagulation is the mainstay of treatment for thrombotic diseases, and novel therapeutics targeting the underlying mechanisms of platelet activation and thrombus formation are under investigation.

This Special Issue aims to show the latest achievements in the field of antibody-mediated thrombotic diseases, including, but not restricted to, clinical presentations, pathophysiological studies, current treatment progress, and future therapeutic perspectives, in order to obtain a comprehensive view of the state of the art of new trends in this area.

Prof. Dr. Tamam Bakchoul
Dr. Günalp Uzun
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• thrombotic diseases
• thrombotic thrombocytopenic purpura
• TTP
• heparin-induced thrombocytopenia
• HIT
• vaccine-induced immune thrombotic thrombocytopenia
• VITT
• antiphopholipid syndrome
• APS